Cleavage of poly(ADP-ribose) transferase during p53-independent apoptosis in rat liver after treatment with N-nitrosomorpholine and cyproterone acetate

Molecular Carcinogenesis

Volumn 24, Issue 4, 1999, Pages 263-275

  Wȩsierska Ga̧dek, Józefa ^a,b   Bugajska Schretter, Agnes ^a   Löw Baselli, Alexandra ^a   Grasl Kraupp, Bettina ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Inst of Tumorbiology Cancer Res   (Austria)

Author keywords

Apoptosis; Cleavage of pADPRT; p21; p53 activation; Regression of liver hyperplasia

Indexed keywords

CYPROTERONE ACETATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITROSOMORPHOLINE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; FEMALE; IMMUNOBLOTTING; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CARCINOGENS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYPROTERONE ACETATE; DNA REPLICATION; FEMALE; GENE EXPRESSION REGULATION; GENES, P53; GLYCOSIDE HYDROLASES; GRANZYMES; HYPERPLASIA; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MITOGENS; NECROSIS; NITROSAMINES; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; SPECIFIC PATHOGEN-FREE ORGANISMS; TESTIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2542509324     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199904)24:4<263::AID-MC4>3.0.CO;2-8     Document Type: Article

References (71)

1. Bursch W, Oberhammer F, Schulte Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992;13:245-251.
2. Schulte-Hermann R, Bursch W, Grasl-Kraupp B. Active cell death (apoptosis) in liver biology and disease. In: Boyer JL, Ockner RK, editors. Progress in liver diseases. p. 1-35. W.B. Saunders; 1995.
3. Bursch W, Taper HS, Lauer B, Schulte-Hermann R. Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchovs Arch B 1985;50:153-166.
4. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Oberhammer F, Wagner A. Programmed cell death and its protective role with particular reference to apoptosis. Toxicol Lett 1992;64/ 65:569-574.
5. Oberhammer F, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor-β1. Proc Natl Acad Sci USA 1992;89:5408-5412.
6. Müllauer L, Grasl-Kraupp B, Bursch W, Schulte-Hermann R. Transforming growth factor β1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology 1996;23:840-847.
7. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA 1994;91:9995-9999.
8. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. BioEssays 1995;17:501-508.
9. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205.
10. Ullrich SJ, Anderson CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992;267:15259-15262.
11. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-868.
12. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-526.
13. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984;308:199-201.
14. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984;4:1689-1694.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
16. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-318.
17. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell 1993;75:765-778.
18. Eliyahu D, Michalovitz D, Eliyahu S, Pinhashi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989;86:8763-8767.
19. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
20. 1 phase. Proc Natl Acad Sci USA 1992;89:9210-9214.
21. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
22. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89:4495-4499.
23. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
24. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
25. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-49.
26. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complex. Mol Cell Biol 1992;12:2866-2871.
27. Smith ML, Chen I-T, Zhan Q, et al. Interaction of the p53-regulated protein Gadd 45 with proliferating cell nuclear antigen. Science 1994;266:1376-1380.
28. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-1245.
29. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-825.
30. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
31. Flores-Rozas H, Kelman Z, Dean FB, et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc Natl Acad Sci USA 1994;91:8655-8659.
32. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
33. Mowat MR. p53 in tumor progression: Life, death and everything. Adv Cancer Res 1998;74:25-48.
34. Yonish-Rouach E, Deguin V, Zaitchouk T, et al. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 1995;11:2197-2205.
35. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Rad Res 1985;101:4-15.
36. Shall S. ADP-ribose in DNA repair. In: Hayaishi O, Ueda K, editors. ADP-ribosylation reactions. London: Academic Press; 1982:477-520.
37. Ueda K, Hayaishi O. ADP-ribosylation. Ann Rev Biochem 1985;54:73-100.
38. Wesierska-Gadek J, Bugajska-Schretter A, Cerni C. ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified. J Cell Biochem 1996;62:90-101.
39. Wesierska-Gadek J, Schmid G, Cerni C. ADP-ribosylation of wild-type p53 in vitro: Binding of p53 protein to specific p53 consensus sequence prevents its modification. Biochem Biophys Res Commun 1996;224:96-102.
40. Whitacre CM, Hashimoto H, Tsai M-L, Chatterjee S, Berger SJ, Berger NA. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res 1995;55:3697-3701.
41. Agarwal ML, Agarwal A, Taylor WR, Wang Z-Q, Wagner EF, Stark GR. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase. Oncogene 1997;15:1035-1041.
42. Wesierska-Gadek J, Wang Z-Q, Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP deficient mice cells. Cancer Res 1999;59:28-34.
43. Schulte-Hermann R. Two-stage control of cell proliferation induced in rat liver by α-hexachlorocyclohexane. Cancer Res 1977;37:166-171.
44. Giner H, Simonin F, de Murcia G, Menissier-de Murcia J. Over-production and large-scale purification of the human poly(ADP-ribose) polymerase using a baculovirus expression system. Gene 1992;114:279-283.
45. Mosgoeller W, Steiner M, Hozak P, Penner E, Wesierska-Gadek J. Nuclear architecture and ultrastructural distribution of poly(ADP-ribosyl)transferase, a multifunctional enzyme. J Cell Sci 1996;109:409-418.
46. Foley J, Ton T, Maronpot R, Butterworth B, Goldsworthy TL. Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferating hepatocytes in rats. Environ Health Perspect 1993;101 (suppl 5):199-206.
47. Tata JR. Isolation of nuclei from rat liver and other tissues. Methods Enzymol 1974;31:253-262.
48. Menard L, Poirier GG. Rapid assay of poly(ADP-ribose) glycohydrolase. Biochem Cell Biol 1987;65:668-673.
49. Wesierska-Gadek J, Sauermann G. Modification of nuclear matrix proteins by ADP-ribosylation. Association of nuclear ADP-ribosyltransferase with the nuclear matrix. Eur J Biochem 1985;153:421-428.
50. n glycohydrolase from human erythrocytes. Eur J Biochem 1990;191:57-63.
51. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
52. Simonin F, Briand J-P, Muller S, de Murcia G. Detection of poly(ADP-ribose) polymerase in crude extracts by activity-blot. Anal Biochem 1991;195:226-231.
53. Grasl-Kraupp B, Ruttkay-Nedecky B, Müllauer L, et al. Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression. Hepatology 1997;25:906-912.
54. Brambilla G, Carlo P, Finollo R, Sciaba L. Dose-response curves for liver DNA fragmentation induced in rats by sixteen N-nitroso compounds as measured by viscometric and alkaline elution analyses. Cancer Res 1987;47:3485-3491.
55. Bellamy COC, Clarke AR, Wyllie AH, Harrison DJ. p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. FASEB J 1997;11:591-599.
56. Midgley CA, Owens B, Briscoe CV, Thomas BD, Lane DP. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108:1843-1848.
57. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human myelogenpus leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 1989;49:5870-5878.
58. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-3985.
59. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-347.
60. Fernandes-Alnemri T, Litwack G, Alnemri ES. Mch2, a new member of the apoptotic CED-3/Ice cysteine protease gene family. Cancer Res 1995;55:2737-2742.
61. Gu Y, Sarnecki C, Aldape RA, Livingston DJ, Su MS-S. Cleavage of poly(ADP-ribose) polymerase by interleukin-1β converting enzyme and its homologs TX and Nedd-2. J Biol Chem 1995;270:18715-18718.
62. Lazebnik YA, Takahashi A, Poirier GG, Kaufmann SH, Earnshaw WC. Characterization of the execution phase of apoptosis in vitro using extracts from condemned-phase cells. J Cell Sci Suppl 1995;19:41-49.
63. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
64. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP-32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-809.
65. Froelich CJ, Hanna WL, Poirier GG, et al. GranzymeB/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-nbose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment. Biochem Biophys Res Commun 1996;227:658-665.
66. Quan LT, Tewari M, O'Rourke K, et al. Proteolytic cleavage of the cell death protease Yama/CPP32 by granzyme B. Proc Natl Acad Sci USA 1996;93:1972-1976.
67. 2+-dependent endonuclease. Proc Natl Acad Sci USA 1975;72:289-293.
68. 2+-dependent endonuclease of bull seminal plasma induced by ADP-ribosylation. J Biol Chem 1984;259:6579-6585.
69. Kuida K, Zheng TS, Na S, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996;384:368-372.
70. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-819.
71. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-726.